(Q43681759)

25 November 2017

title

A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy (English)

1 reference

25 November 2017

1 reference

1 reference

M Nieto-Barrera

1

1 reference

25 November 2017

M Brozmanova

2

1 reference

25 November 2017

G Capovilla

3

1 reference

25 November 2017

W Christe

4

1 reference

25 November 2017

B Pedersen

5

1 reference

25 November 2017

K Kane

6

1 reference

25 November 2017

F O'Neill

7

1 reference

25 November 2017

Lamictal vs. Carbamazepine Study Group

8

1 reference

25 November 2017

language of work or name

1 reference

1 August 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

46

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

145-155

1 reference

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Serum anticonvulsant concentrations and the risk of drug induced skin eruptions

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

An active-control trial of lamotrigine monotherapy for partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Safety review of adult clinical trial experience with lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900271-6

7 January 2021

10.1016/S0920-1211(01)00271-6

Identifiers

DOI

1 reference

25 November 2017

1 reference